(Q37981602)

26 August 2017

title

HIV medications: an update and review of metabolic complications (English)

1 reference

26 August 2017

E Kelly Hester

1

1 reference

26 August 2017

publication date

1 February 2012

1 reference

Nutrition in Clinical Practice

26 August 2017

published in

1 reference

26 August 2017

volume

27

1 reference

26 August 2017

issue

1

1 reference

26 August 2017

page(s)

51-64

1 reference

Lentivirus replication and regulation

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0884533611431985

Human immunodeficiency virus pathogenesis: insights from studies of lymphoid cells and tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0884533611431985

Estimation of HIV incidence in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0884533611431985

Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0884533611431985

Effect of early versus deferred antiretroviral therapy for HIV on survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0884533611431985

Replication and compartmentalization of HIV-1 in kidney epithelium of patients with HIV-associated nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0884533611431985

Suppression of HIV-1 replication by antiretroviral therapy improves renal function in persons with low CD4 cell counts and chronic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0884533611431985

HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0884533611431985

Prevention of HIV-1 infection with early antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0884533611431985

Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0884533611431985

Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0884533611431985

Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0884533611431985

Antiretroviral-drug resistance among patients recently infected with HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0884533611431985

Prevalence of transmitted drug resistance associated mutations and HIV-1 subtypes in new HIV-1 diagnoses, U.S.-2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0884533611431985

Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0884533611431985

Lipid Metabolism and Cardiovascular Risk in HIV-1 Infection and HAART: Present and Future Problems

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0884533611431985

HIV replication enhances production of free fatty acids, low density lipoproteins and many key proteins involved in lipid metabolism: a proteomics study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0884533611431985

Clinical review 153: Lipodystrophy in human immunodeficiency virus-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0884533611431985

Antiretroviral therapy-associated hyperlipidaemia in HIV disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0884533611431985

HIV protease inhibitors stimulate hepatic triglyceride synthesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0884533611431985

Human immunodeficiency virus (HIV) infects human arterial smooth muscle cells in vivo and in vitro: implications for the pathogenesis of HIV-mediated vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0884533611431985

Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0884533611431985

A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0884533611431985

Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0884533611431985

Efavirenz induces a striking and generalized increase of HDL-cholesterol in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0884533611431985

Combination antiretroviral therapy and the risk of myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0884533611431985

Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0884533611431985

CD4+ count-guided interruption of antiretroviral treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0884533611431985

HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0884533611431985

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0884533611431985

A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0884533611431985

Combination of niacin and fenofibrate with lifestyle changes improves dyslipidemia and hypoadiponectinemia in HIV patients on antiretroviral therapy: results of "heart positive," a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0884533611431985

Characterization of a new circulating recombinant form comprising HIV-1 subtypes C and B in southern Brazil.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0884533611431985

Disorders of glucose metabolism in patients infected with human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0884533611431985

Direct comparison of the acute in vivo effects of HIV protease inhibitors on peripheral glucose disposal

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0884533611431985

Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0884533611431985

Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0884533611431985

Indinavir inhibits the glucose transporter isoform Glut4 at physiologic concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0884533611431985

Effects of a nucleoside reverse transcriptase inhibitor, stavudine, on glucose disposal and mitochondrial function in muscle of healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0884533611431985

Approach to the human immunodeficiency virus-infected patient with lipodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0884533611431985

Metabolic effects of indinavir in healthy HIV-seronegative men

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0884533611431985

Effects of ritonavir-boosted darunavir vs. ritonavir-boosted atazanavir on lipid and glucose parameters in HIV-negative, healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0884533611431985

Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0884533611431985

Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0884533611431985

Improvement in insulin sensitivity and dyslipidemia in protease inhibitor-treated adult male patients after switch to atazanavir/ritonavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0884533611431985

Switching to unboosted atazanavir improves glucose tolerance in highly pretreated HIV-1 infected subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0884533611431985

Sustained benefits of metformin therapy on markers of cardiovascular risk in human immunodeficiency virus-infected patients with fat redistribution and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0884533611431985

Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0884533611431985

Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0884533611431985

Metabolic basis of HIV-lipodystrophy syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0884533611431985

Hypoadiponectinemia is associated with insulin resistance, hypertriglyceridemia, and fat redistribution in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0884533611431985

Human immunodeficiency virus type 1-related lipoatrophy and lipohypertrophy are associated with serum concentrations of leptin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0884533611431985

A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0884533611431985

Treatment of HIV lipoatrophy and lipoatrophy of aging with poly-L-lactic acid: a prospective 3-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0884533611431985

Pathogenesis and treatment of HIV lipohypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0884533611431985

Metabolic effects of a growth hormone-releasing factor in patients with HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0884533611431985

Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0884533611431985

Bone remodelling in human immunodeficiency virus-1-infected patients. A histomorphometric study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0884533611431985

Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0884533611431985

Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0884533611431985

Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0884533611431985

Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0884533611431985

Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0884533611431985

Relationship between low bone mineral density and highly active antiretroviral therapy including protease inhibitors in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0884533611431985

Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0884533611431985

The HIV protease inhibitor ritonavir blocks osteoclastogenesis and function by impairing RANKL-induced signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0884533611431985

Efavirenz-induced osteomalacia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0884533611431985

Vitamin D deficiency among HIV type 1-infected individuals in the Netherlands: effects of antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0884533611431985

Efavirenz is associated with severe vitamin D deficiency and increased alkaline phosphatase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0884533611431985

High frequency of vitamin D deficiency in ambulatory HIV-Positive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0884533611431985

HIV-protease inhibitors impair vitamin D bioactivation to 1,25-dihydroxyvitamin D.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0884533611431985

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0884533611431985

Vitamin D status and response to treatment in post-menopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0884533611431985

Bone disease in HIV infection: a practical review and recommendations for HIV care providers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0884533611431985

Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0884533611431985

Annual zoledronate increases bone density in highly active antiretroviral therapy-treated human immunodeficiency virus-infected men: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0884533611431985

Guidelines for the Evaluation and Management of Dyslipidemia in Human Immunodeficiency Virus (HIV)-Infected Adults Receiving Antiretroviral Therapy: Recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0884533611431985

21 January 2018

Identifiers

DOI

10.1177/0884533611431985

1 reference

26 August 2017

1 reference